Here’s how analysts see Lannett Company, Inc. (NYSE:LCI) after this past week.

February 21, 2018 - By Marguerite Chambers

 Here's how analysts see Lannett Company, Inc. (NYSE:LCI) after this past week.
Investors sentiment increased to 1.48 in Q3 2017. Its up 0.60, from 0.88 in 2017Q2. It increased, as 13 investors sold Lannett Company, Inc. shares while 37 reduced holdings. 24 funds opened positions while 50 raised stakes. 27.62 million shares or 13.83% less from 32.05 million shares in 2017Q2 were reported.
Hartford Investment Management Communications has 11,500 shares for 0% of their portfolio. Focused Wealth Mngmt holds 4,200 shares. Nordea Invest Ab has invested 0.01% in Lannett Company, Inc. (NYSE:LCI). Legal & General Gru Public Ltd Co invested in 55,377 shares or 0% of the stock. Prudential invested in 0% or 48,908 shares. Acadian Asset Management Limited Liability Corp stated it has 97 shares. Tower Cap (Trc) reported 3,042 shares. California Public Employees Retirement Sys stated it has 81,146 shares. Moreover, Parametric Portfolio Assoc Lc has 0.01% invested in Lannett Company, Inc. (NYSE:LCI) for 444,557 shares. 67,682 are owned by Raymond James And Assoc. Balyasny Asset Management Ltd Limited Liability Company holds 0% or 35,000 shares. Huntington Financial Bank holds 0% in Lannett Company, Inc. (NYSE:LCI) or 188 shares. Bridgeway Capital Mngmt Inc reported 0.02% in Lannett Company, Inc. (NYSE:LCI). Moreover, Teachers Retirement Of The State Of Kentucky has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 9,900 shares. Amer Intl Gp stated it has 0% in Lannett Company, Inc. (NYSE:LCI).

Since December 13, 2017, it had 0 insider buys, and 2 sales for $255,620 activity.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Among 11 analysts covering Lannett (NYSE:LCI), 6 have Buy rating, 1 Sell and 4 Hold. Therefore 55% are positive. Lannett had 30 analyst reports since July 21, 2015 according to SRatingsIntel. As per Thursday, February 8, the company rating was maintained by BMO Capital Markets. On Thursday, March 24 the stock rating was maintained by Roth Capital with “Buy”. The stock has “Buy” rating by Roth Capital on Thursday, September 3. The company was upgraded on Thursday, February 4 by Craig Hallum. The company was upgraded on Monday, September 7 by Zacks. Oppenheimer maintained Lannett Company, Inc. (NYSE:LCI) on Thursday, June 8 with “Hold” rating. Deutsche Bank maintained the shares of LCI in report on Monday, August 14 with “Hold” rating. Raymond James maintained the shares of LCI in report on Wednesday, August 24 with “Outperform” rating. TH Capital maintained the shares of LCI in report on Thursday, September 3 with “Buy” rating. The rating was maintained by Roth Capital with “Buy” on Wednesday, February 7. Below is a list of Lannett Company, Inc. (NYSE:LCI) latest ratings and price target changes.

07/02/2018 Broker: Roth Capital Rating: Buy New Target: $25.0 Maintain
08/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $22 New Target: $21 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $21 Initiates Coverage On
01/12/2017 Broker: Raymond James Rating: Buy
13/11/2017 Broker: BMO Capital Markets Rating: Market Perform Old Target: $20 New Target: $22 Maintain
23/08/2017 Broker: Oppenheimer Rating: Hold Maintain
22/08/2017 Broker: Roth Capital Rating: Buy New Target: $27.0 Maintain

The stock decreased 4.40% or $0.75 during the last trading session, reaching $16.3. About 904,286 shares traded or 17.38% up from the average. Lannett Company, Inc. (NYSE:LCI) has declined 2.16% since February 21, 2017 and is downtrending. It has underperformed by 18.86% the S&P500.

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company has market cap of $616.85 million. The firm offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It has a 12.72 P/E ratio. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout.

More important recent Lannett Company, Inc. (NYSE:LCI) news were published by: which released: “Lannett Announces Fiscal 2018 Second-Quarter Financial Results; Reports Record …” on February 07, 2018, also published article titled: “Why Lannett Company, Inc. Is Falling Today”, published: “Lannett Enters Into Consulting Agreement With Former CEO, Arthur Bedrosian” on February 01, 2018. More interesting news about Lannett Company, Inc. (NYSE:LCI) was released by: and their article: “Lannett Company Inc.: Lannett To Report Fiscal 2018 Second-Quarter Financial …” with publication date: January 31, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.